Curatis will apply for a Biologic License for C-PTBE-01 in the USA - this will significantly increase the duration of market protection in the USA in the event of approval

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Research

Pharmaceutical

Science

Biotechnology

Curatis Holding

More Like This

Curatis on track: submission of orphan drug designation application in the US for lead product candidate

Curatis: Sales growth of 30% in distribution - plus significant expansion of patient target group for lead project C-PTBE-01

Curatis discloses Corticorelin as active substance of C-PTBE-01

Curatis: Significantly Increased Sales in Core Business and Projects in Development Pipeline on Track

Merus Receives FDA extension of PDUFA for zenocutuzumab

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update